Gilead Said In Deals With Five Pharmas To Market Hep C Generics
This article was originally published in PharmAsia News
Executive Summary
Gilead Sciences reportedly is signing deals with Zydus Cadila, Cipla, Hetero, Mylan and Strides Arcolab for marketing generic versions of two of the U.S. drug maker's hepatitis C treatments.